Effect of budesonide formoterol powder inhalation combined with spleen aminopeptide in treatment of patients with acute attack of bronchial asthma

  Objective  To observe the effect of budesonide formoterol powder inhalation combined with spleen aminopeptide in treatment of patients with acute attack of bronchial asthma.

  Methods  A total of 98 patients with acute attack of bronchial asthma were randomly divided into control group and study group, with 49 cases in each group. The control group was treated with budesonide formoterol, while the study group was treated with budesonide formoterol and spleen aminopeptide. Improvement of symptoms, lung function indexesforced expiratory volume in the first second (FEV₁), ratio of forced expiratory volume in the first second to forced vital capacity (FEV₁/FVC), maximum peak expiratory flow rate in the morning (PEF_am) and maximum peak expiratory flow rate in the evening (PEF_pm), helper T cell 1/helper T cell 2(Th1/Th2) drift and microRNA-146a (miR-146a) expression level were compared between the two groups.

  Results  The improvement time of symptoms such as asthma, cough, wheezing and wet rale in the study group was significantly shorter than that in the control group (P < 0.05). After treatment, FEV₁, FEV₁/FVC, PEF_am and PEF_pm in both groups were significantly higher than those before treatment, and FEV₁, FEV₁/FVC, PEF_am and PEF_pm in the study group were significantly higher than those in the control group (P < 0.05). After treatment, interleukin-2 (IL-2), interferon-γ (IFN-γ), Th1 and Th1/Th2 increased significantly, while interleukin-5 (IL-5), interleukin-13 (IL-13) and Th2 decreased significantly in both groups, and IL-2, IFN-γ, Th1 and Th1/Th2 in the study group were significantly higher than those in the control group, while IL-5, IL-13 and Th2 were significantly lower than those in the control group (P < 0.05). After treatment, the expression level of miR-146a in both groups was significantly lower than that before treatment, and the expression level of miR-146a in the study group was significantly lower than that in the control group (P < 0.05).

  Conclusion  Budesonide formoterol combined with spleen aminopeptide has a significant effect in the treatment of patients with acute attack of bronchial asthma, which can accelerate the remission of symptoms and improve lung function, and its mechanism may be related to reversing the drift direction of Th1/Th2 and down-regulating the expression level of miR-146a.